News
GSK’s share price is still significantly down on the year, despite very robust H1 results, leaving it looking extremely ...
British drugmaker GSK said on Monday that the U.S. Food and Drug Administration has accepted its application for priority ...
London: GSK plc has announced that a supplemental New Drug Application for gepotidacin has been accepted by the US Food and ...
1d
InvestorsHub on MSNGSK shares rise after FDA grants priority review for oral gonorrhea antibiotic
GSK (NYSE:GSK) announced Monday that the U.S. Food and Drug Administration has accepted its priority review application for ...
Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...
The pharma giant will also receive a 1% royalty on future U.S. sales of influenza, Covid-19 and other related combination ...
With a portfolio of 14 potential blockbuster treatments that it expects to launch over the next five years, GSK is sticking ...
Having recently scored approval for Nucala in chronic obstructive pulmonary disease (COPD), GSK has now signed a major ...
The deal, which focuses first on a COPD drug GSK believes holds “best-in-class” potential, could involve a dozen medicines ...
GSK PLC GSK shares rose 4.69% to £14.63 Wednesday, on what proved to be an all-around favorable trading session for the stock ...
GSK is paying $500M upfront for rights to a series of Hengrui drugs, the latest case of a pharma company looking to a Chinese ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results